BlackBarn Capital Partners LP In its 13F for Q1 2026 (holdings as of March 31, 2026, filed May 15, 2026), BlackBarn Capital Partners LP reported 14 stock positions worth $332.4 million . Its top holding was Roivant Sciences (ROIV) at 19.0% of the portfolio, followed by Veeco Instruments (VECO, 10.2% ) and Privia Health (PRVA, 9.8% ). Compared with Q4 2025, it opened 4 new positions, sold out of 1, added to 6 and reduced 3. The biggest buy was a new position in Veeco Instruments (VECO) and the biggest sale Roivant Sciences (ROIV, shares −26% ).
Location NEW YORK, NY
CIK 0002010204
Portfolio Value $332.4M (Q1 2026) Holdings 14 stocks · $332.4M Holdings quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock % Of Portfolio ▼ Shares Held Total Value Change vs Q4 2025 ROIV Roivant Sciences Ltd. 2,285,117 $63.3M Reduce -25.9% VECO Veeco Instruments Inc. 1,000,000 $33.9M New PRVA Privia Health Group Inc. 1,585,000 $32.6M Add +21.9% DHC Diversified Healthcare Trust 4,812,413 $32.0M Reduce -26.3% NEE Nextera Energy Inc. 335,000 $31.1M No change MH McGraw Hill Inc. 2,088,492 $28.6M Add +49.2% NIQ Niq Global Intelligence PLC 2,074,761 $23.6M Add +15.3% AMRX Amneal Pharmaceuticals Inc. 1,650,000 $20.5M Add +5.1% VKTX Viking Therapeutics Inc. 621,450 $20.2M Add +13.0% NXPI NXP Semiconductors NV 60,000 $11.8M New ABUS Arbutus Biopharma Corp. 2,500,000 $11.3M Add +35.1% GBTG Global Business Travel Group 2,000,000 $11.2M New CCOI Cogent Communications Holdin 500,000 $9.4M Reduce -23.1% SEAT Vivid Seats Inc. Class A 500,000 $3.0M New
Options reported separately and not counted above: SPY puts ($520.3M), EWZ puts ($201.5M), RMD puts ($89.8M), AAL puts ($43.0M), PLTR puts ($25.6M), WRBY puts ($21.1M), CCOI puts ($9.4M).
Portfolio Sells Q4 2025 → Q1 2026 Portfolio Sells quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2025 % Of Portfolio Change To Portfolio ▲ ROIV Roivant Sciences Ltd. Reduce -25.9% 19.04% −4.95 ACLS Axcelis Technologies Inc. Sold out 0.00% −2.78 CCOI Cogent Communications Holdin Reduce -23.1% 2.83% −2.19 DHC Diversified Healthcare Trust Reduce -26.3% 9.61% −1.74
Portfolio Buys Q4 2025 → Q1 2026 Portfolio Buys quarter Q2 2026 Q1 2026 Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024
Stock Change vs Q4 2025 % Of Portfolio Change To Portfolio ▼ VECO Veeco Instruments Inc. New 10.19% +10.19 NXPI NXP Semiconductors NV New 3.55% +3.55 GBTG Global Business Travel Group New 3.36% +3.36 SEAT Vivid Seats Inc. Class A New 0.89% +0.89 MH McGraw Hill Inc. Add +49.2% 8.61% +0.33 ABUS Arbutus Biopharma Corp. Add +35.1% 3.38% +0.19 VKTX Viking Therapeutics Inc. Add +13.0% 6.08% −0.85 AMRX Amneal Pharmaceuticals Inc. Add +5.1% 6.17% −0.92 PRVA Privia Health Group Inc. Add +21.9% 9.81% −1.24 NIQ Niq Global Intelligence PLC Add +15.3% 7.10% −3.54
Options Activity Q4 2025 → Q1 2026 Security Type Change vs Q4 2025 Underlying Shares Value ▼ SPY SS SPDR S&P 500 ETF Trust-US put Reduce -46.7% 800,000 $520.3M EWZ iShares MSCI Brazil ETF put New 5,250,000 $201.5M AAL American Airlines Group Inc. put New 4,000,000 $43.0M ELAN Elanco Animal Health Inc. put Sold out 1,700,000 $38.5Mbefore exit PLTR Palantir Technologies Inc. Class A put New 175,000 $25.6M WRBY Warby Parker Inc. Class A put Reduce -66.7% 1,000,000 $21.1M OSCR Oscar Health Inc. Class A put Sold out 1,300,000 $18.7Mbefore exit CCOI Cogent Communications Holdin put New 500,000 $9.4M
Calls and puts are listed by the shares they cover; their value is not part of the stock holdings above.
All Filings Quarter Positions 13F Reported Value Top Holdings Q2 2026 17 $402.2M ROIV, PRVA, DHC, NEE, NIQ Q1 2026 14 $332.4M ROIV, VECO, PRVA, DHC, NEE Q4 2025 11 $278.9M ROIV, DHC, PRVA, NIQ, NEE Q3 2025 15 $306.4M ROIV, PRVA, DHC, NXT, AMRX Q2 2025 20 $301.8M ROIV, AMRX, ACLS, DHC, MOH Q1 2025 18 $292.8M ROIV, UNH, MOH, AMRX, ACLS Q4 2024 15 $254.1M ROIV, UNH, MOH, TEVA, AMRX Q3 2024 18 $230.1M ROIV, MOH, AMRX, DHC, T Q2 2024 17 $194.0M ROIV, UNH, MOH, AMRX, BRBS Q1 2024 21 $173.0M ROIV, MOH, UNH, CHRD, CF